Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Roferon-A

Roferon-A is a medicine containing the active ingredient(s) interferon alfa-2a. On this page you will find out more about Roferon-A, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: interferon alfa-2a

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Roferon-A 9 million units/0.5 mL injection solution, 0.5 mL syringe

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

ROFERON-A is indicated for use in the treatment of: AIDS-related Kaposi's sarcoma; patients with histologically proven chronic active hepatitis B (but without evidence of cirrhosis of the liver) and raised ALT levels (>3 x upper limit of reference range); Chronic hepatitis C given in combination with ribavirin in previously untreated patients or patients who have relapsed following alfa interferon monotherapy. Patients must be 18 years of age and have compensated liver disease; patients 18 years or older with histologically proven chronic hepatitis due to hepatitis C and persistently elevated serum ALT for at least 6 months and without liver decompensation (Child's Class A); hairy cell leukaemia; chronic myelogenous leukaemia; (CML) and excessive thrombocytosis associated with CML and other myeloproliferative disorders, in people 18 years of age or older; cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome); patients with low-grade non-Hodgkin's lymphoma (as per international working formulation) when used as an adjunct to or concomitant with chemotherapy (with or without radiotherapy) ; advanced and/or metastatic renal cell carcinoma.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear to slightly yellowish liquid that is practically free from particles (max Y5 Ph.Eur.)
Dosage Form Injection, solution
Route of administration Subcutaneous
Medicine schedule
1 x 0.5mL prefilled syringe: Prescription Only Medicine, or Prescription Animal Remedy
5 x 0.5mL prefilled syringes: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Syringe
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Protect from Light
Life time 2 Years
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 April 2018

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo